5.8 USD
+0.05 (+0.87%)
5.8 USD
0 (0%)
We assign a fundamental rating of 3 out of 10 to KRMD. KRMD was compared to 187 industry peers in the Health Care Equipment & Supplies industry. While KRMD seems to be doing ok healthwise, there are quite some concerns on its profitability. KRMD is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year KRMD has reported negative net income.
KRMD had a positive operating cash flow in the past year.
KRMD had negative earnings in each of the past 5 years.
In the past 5 years KRMD always reported negative operating cash flow.
1.2 Ratios
KRMD has a Return On Assets of -13.70%. This is comparable to the rest of the industry: KRMD outperforms 58.29% of its industry peers.
With a decent Return On Equity value of -22.55%, KRMD is doing good in the industry, outperforming 60.43% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.7% | ||
| ROE | -22.55% | ||
| ROIC | N/A |
ROA(3y)-30.34%
ROA(5y)-21.02%
ROE(3y)-43.74%
ROE(5y)-29.41%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
KRMD's Gross Margin of 62.32% is fine compared to the rest of the industry. KRMD outperforms 63.64% of its industry peers.
KRMD's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for KRMD so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 62.32% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.65%
GM growth 5Y-0.23%
2. Health
2.1 Basic Checks
KRMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
KRMD has more shares outstanding than it did 1 year ago.
The number of shares outstanding for KRMD has been increased compared to 5 years ago.
Compared to 1 year ago, KRMD has an improved debt to assets ratio.
2.2 Solvency
KRMD has an Altman-Z score of 14.86. This indicates that KRMD is financially healthy and has little risk of bankruptcy at the moment.
KRMD's Altman-Z score of 14.86 is amongst the best of the industry. KRMD outperforms 93.05% of its industry peers.
KRMD has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.03, KRMD is doing good in the industry, outperforming 70.05% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 14.86 |
ROIC/WACCN/A
WACC8.76%
2.3 Liquidity
KRMD has a Current Ratio of 2.48. This indicates that KRMD is financially healthy and has no problem in meeting its short term obligations.
KRMD has a Current ratio (2.48) which is comparable to the rest of the industry.
KRMD has a Quick Ratio of 1.92. This is a normal value and indicates that KRMD is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of KRMD (1.92) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.48 | ||
| Quick Ratio | 1.92 |
3. Growth
3.1 Past
KRMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 30.00%, which is quite impressive.
The Revenue has grown by 22.12% in the past year. This is a very strong growth!
KRMD shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 7.76% yearly.
EPS 1Y (TTM)30%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)22.12%
Revenue growth 3Y12.72%
Revenue growth 5Y7.76%
Sales Q2Q%27.18%
3.2 Future
The Earnings Per Share is expected to grow by 34.04% on average over the next years. This is a very strong growth
KRMD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 17.65% yearly.
EPS Next Y28.6%
EPS Next 2Y34.77%
EPS Next 3Y34.04%
EPS Next 5YN/A
Revenue Next Year20.76%
Revenue Next 2Y19.69%
Revenue Next 3Y17.65%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for KRMD. In the last year negative earnings were reported.
Also next year KRMD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as KRMD's earnings are expected to grow with 34.04% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.77%
EPS Next 3Y34.04%
5. Dividend
5.1 Amount
KRMD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
5.8
+0.05 (+0.87%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners56.97%
Inst Owner ChangeN/A
Ins Owners8.38%
Ins Owner Change1.57%
Market Cap268.66M
Revenue(TTM)39.07M
Net Income(TTM)-3.71M
Analysts80
Price Target5.76 (-0.69%)
Short Float %2.29%
Short Ratio6.96
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)64.99%
Min EPS beat(2)29.97%
Max EPS beat(2)100%
EPS beat(4)4
Avg EPS beat(4)39.61%
Min EPS beat(4)3.88%
Max EPS beat(4)100%
EPS beat(8)8
Avg EPS beat(8)38.65%
EPS beat(12)12
Avg EPS beat(12)33.06%
EPS beat(16)15
Avg EPS beat(16)30.05%
Revenue beat(2)2
Avg Revenue beat(2)5.58%
Min Revenue beat(2)5.51%
Max Revenue beat(2)5.66%
Revenue beat(4)3
Avg Revenue beat(4)3.78%
Min Revenue beat(4)-2.56%
Max Revenue beat(4)6.5%
Revenue beat(8)7
Avg Revenue beat(8)4.72%
Revenue beat(12)7
Avg Revenue beat(12)1.12%
Revenue beat(16)11
Avg Revenue beat(16)2.1%
PT rev (1m)0.89%
PT rev (3m)0.89%
EPS NQ rev (1m)-9.17%
EPS NQ rev (3m)-9.17%
EPS NY rev (1m)12.5%
EPS NY rev (3m)9.68%
Revenue NQ rev (1m)0.12%
Revenue NQ rev (3m)0.12%
Revenue NY rev (1m)1.89%
Revenue NY rev (3m)1.89%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 6.88 | ||
| P/FCF | N/A | ||
| P/OCF | 874.53 | ||
| P/B | 16.32 | ||
| P/tB | 17.02 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.07
EYN/A
EPS(NY)-0.02
Fwd EYN/A
FCF(TTM)0
FCFYN/A
OCF(TTM)0.01
OCFY0.11%
SpS0.84
BVpS0.36
TBVpS0.34
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.7% | ||
| ROE | -22.55% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 62.32% | ||
| FCFM | N/A |
ROA(3y)-30.34%
ROA(5y)-21.02%
ROE(3y)-43.74%
ROE(5y)-29.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.65%
GM growth 5Y-0.23%
F-Score5
Asset Turnover1.44
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 57.64% | ||
| Cap/Sales | 1.24% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.48 | ||
| Quick Ratio | 1.92 | ||
| Altman-Z | 14.86 |
F-Score5
WACC8.76%
ROIC/WACCN/A
Cap/Depr(3y)239.72%
Cap/Depr(5y)210.83%
Cap/Sales(3y)5.63%
Cap/Sales(5y)4.58%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y28.6%
EPS Next 2Y34.77%
EPS Next 3Y34.04%
EPS Next 5YN/A
Revenue 1Y (TTM)22.12%
Revenue growth 3Y12.72%
Revenue growth 5Y7.76%
Sales Q2Q%27.18%
Revenue Next Year20.76%
Revenue Next 2Y19.69%
Revenue Next 3Y17.65%
Revenue Next 5YN/A
EBIT growth 1Y43.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year104.66%
EBIT Next 3Y45.91%
EBIT Next 5YN/A
FCF growth 1Y96.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y106.61%
OCF growth 3YN/A
OCF growth 5YN/A
KORU MEDICAL SYSTEMS INC / KRMD FAQ
What is the ChartMill fundamental rating of KORU MEDICAL SYSTEMS INC (KRMD) stock?
ChartMill assigns a fundamental rating of 3 / 10 to KRMD.
What is the valuation status of KORU MEDICAL SYSTEMS INC (KRMD) stock?
ChartMill assigns a valuation rating of 1 / 10 to KORU MEDICAL SYSTEMS INC (KRMD). This can be considered as Overvalued.
Can you provide the profitability details for KORU MEDICAL SYSTEMS INC?
KORU MEDICAL SYSTEMS INC (KRMD) has a profitability rating of 2 / 10.
How financially healthy is KORU MEDICAL SYSTEMS INC?
The financial health rating of KORU MEDICAL SYSTEMS INC (KRMD) is 5 / 10.